2022 noqon kara: Trametinib waxa laga yaabaa inay noqoto heer cusub oo daryeel loogu talagalay kansarka ugxan-sidaha ee soo noqnoqda, heerka hooseeya (Mekinist). Sida laga soo xigtay natiijooyinka daraasadda ee lagu daabacay daabacaadda Febraayo 2022 ee Lancet, trametinib waxay garaacday labadaba kiimoterabiga iyo anti-estrogens sida tamoxifen qiyaastii 52 boqolkiiba, iyada oo ku dartay lix bilood oo horumar la'aan ah (muddada uu kansarku uusan horay u marin) badbaadada bukaanka.
260 haween ah oo qaba burooyinka ugxan-sidaha ee soo noqnoqda kuwaas oo hore u helay kiimoterabi, cilmi-baarayaal ka socda Maraykanka iyo Boqortooyada Ingiriiska ayaa barbardhigay trametinib afka hal mar maalinlaha ah mid ka mid ah shanta heer ee daryeelka caafimaadka (ama kiimoterabi ama daawooyinka estrogen-ka-hortagga). Marka la barbardhigo daaweynta caadiga ah, kaqeybgalayaasha trametinib waxay muujiyeen jawaab celin afar laab ah oo ka sareysa daaweynta 15 bilood ka dib. Trametinib waxa uu ka fiicnaaday dhammaan daawaynta kale, hoos u dhigaysa horumarka cudurka muddo 13 bilood ah (marka laga reebo todoba bilood oo daawaynta caadiga ah). Finanka maqaarka, dhiig-yaraan, cadaadis dhiig oo sarreeya, shuban, iyo daal ayaa ah qaar ka mid ah saameynta xun ee khatarta ah ee daaweynta trametinib.
Low-grade serous kansarka ugxansiduhu is a difficult-to-treat invasive form of ovarian cancer marked by strong hormone receptor activation, genetic alterations, and poor chemotherapy response. Until now, the cancer toolbox lacked effective therapeutic options for patients with low-grade serous ovarian cancer. According to an editorial accompanying the report, 70% of these women will recur, with only 5% responding to further chemotherapy.
